Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Targeting the Sonic Hedgehog Pathway in Chronic Myeloid Leukemia Stem Cells with a Novel Combination Therapy

EF 2015-16

Résumé
Chronic myeloid leukemia (CML) is a lethal malignancy that results from a translocation of a portion of chromosomes 9 and 22 in a hematopoietic stem cell. This translocation creates a pathogenic fusion protein that initiates leukemia by deregulating cellular processes such as cell proliferation, cell death, and genomic stability. Though an effective molecularly targeted treatment is available, initial and acquired resistance to the drug, imatinib mesylate (IM), remain a problem. Though IM is effective at clearing the bulk of the mature leukemia cells, it is ineffective against the CML stem cells, which sustain the disease and promote relapse. One pathway that is important for stem cell survival is the Sonic hedgehog (Shh) signalling pathway. A constituent of this pathway is the Smoothened (SMO) protein, which is frequently mutated in other cancers including basal cell carcinoma (BCC), the most prevalent form of skin cancer. I propose that a novel combination treatment of bosutinib, a drug with a similar action to IM, with a SMO inhibitor can prevent the growth of CML stem cells and abrogate drug resistance in CML patients. I plan to validate this by performing various experiments in CML cell lines and primary patient samples. Importantly, CML is a model cancer in which many of the underlying mechanisms of initiation and progression are well understood. By investigating the role of the Shh pathway in this pre-clinical drug study in CML, I aim to uncover crucial mechanisms applicable to other types of cancer, providing a novel therapeutic target.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
349928
Name
Turner Kelly A
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Targeting the Sonic Hedgehog Pathway in Chronic Myeloid Leukemia Stem Cells with a Novel Combination Therapy
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Chronic Myeloid Leukemia; Drug Resistance; Sonic Hedgehog Signaling Pathway; Stem Cells; Translational Research; Treatment Strategies
Abstract
Chronic myeloid leukemia (CML) is a lethal malignancy that results from a translocation of a portion of chromosomes 9 and 22 in a hematopoietic stem cell. This translocation creates a pathogenic fusion protein that initiates leukemia by deregulating cellular processes such as cell proliferation, cell death, and genomic stability. Though an effective molecularly targeted treatment is available, initial and acquired resistance to the drug, imatinib mesylate (IM), remain a problem. Though IM is effective at clearing the bulk of the mature leukemia cells, it is ineffective against the CML stem cells, which sustain the disease and promote relapse. One pathway that is important for stem cell survival is the Sonic hedgehog (Shh) signalling pathway. A constituent of this pathway is the Smoothened (SMO) protein, which is frequently mutated in other cancers including basal cell carcinoma (BCC), the most prevalent form of skin cancer. I propose that a novel combination treatment of bosutinib, a drug with a similar action to IM, with a SMO inhibitor can prevent the growth of CML stem cells and abrogate drug resistance in CML patients. I plan to validate this by performing various experiments in CML cell lines and primary patient samples. Importantly, CML is a model cancer in which many of the underlying mechanisms of initiation and progression are well understood. By investigating the role of the Shh pathway in this pre-clinical drug study in CML, I aim to uncover crucial mechanisms applicable to other types of cancer, providing a novel therapeutic target.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Turner, Kelly A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~